Clinical Trial Update: Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating an anti-PD-1 antibody in a multimodal combination as first-line treatment for advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Anti-PD-1 antibody

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Advanced Solid Tumor | Phase 2 | Status: UNKNOWN